Eseroline

Eseroline
Clinical data
Other names	Eseroline
ATC code	none;
Identifiers
	IUPAC name (3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-ol;
CAS Number	469-22-7 ;
PubChem CID	119198;
ChemSpider	106485;
UNII	Q22H41O18D;
ChEBI	CHEBI:48845;
CompTox Dashboard (EPA)	DTXSID30891448 ;
Chemical and physical data
Formula	C13H18N2O
Molar mass	218.300 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)O)C)C;
	InChI InChI=1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3/t12-,13+/m1/s1; Key:HKGWQUVGHPDEBZ-OLZOCXBDSA-N;
	(verify)

Eseroline is a drug which acts as an opioid agonist. It is a metabolite of the acetylcholinesterase inhibitor physostigmine but unlike physostigmine, the acetylcholinesterase inhibition produced by eseroline is weak and easily reversible, and it produces fairly potent analgesic effects mediated through the μ-opioid receptor. This mixture of activities gives eseroline an unusual pharmacological profile, although its uses are limited by side effects such as respiratory depression and neurotoxicity.